Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06170970 · ClinicalTrials.gov registry record · Phase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

A Phase 2 study of Multiple Sclerosis and Multiple Sclerosis Fatigue, sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 2
Development phase
46
Enrollment target
1
Study location

NCT06170970 is a Phase 2 study of Multiple Sclerosis and Multiple Sclerosis Fatigue that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 46 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06170970, a Phase 2 study of Multiple Sclerosis and Multiple Sclerosis Fatigue, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 2
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for MS patients with concomitant excessive daytime sleepiness. This study uses a randomized, double-blind, placebo-controlled crossover design. Participants will undergo a 10-day lead-in with he medication/placebo, followed by two four-week treatment periods separated by a one-week washout. Outcomes will be measured primarily using the Modified Fatigue Impact Scale (MFIS), with additional exploratory measures collected via a smartphone app that assesses fatigue through keystroke dynamics. This novel approach to fatigue measurement aims to capture real-time variations and provide more granular data than traditional self-report questionnaires.

Conditions Studied

Multiple Sclerosis Multiple Sclerosis Fatigue

Interventions

  • DRUG Placebo
  • DRUG Solriamfetol

Study Locations (1)

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2024-06-01
Est. Completion 2027-03-01
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06170970

The ClinicalTrials.gov registry entry for NCT06170970 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (92% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06170970 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT06170970 about?

NCT06170970 is a clinical study titled "Solriamfetol for the Treatment of Multiple Sclerosis Fatigue". Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for...

What is the current status of trial NCT06170970?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2024-06-01. Estimated completion is 2027-03-01.

What conditions does trial NCT06170970 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis Fatigue.

What interventions are being tested in trial NCT06170970?

The interventions under investigation include: Placebo (DRUG), Solriamfetol (DRUG).

Who is sponsoring clinical trial NCT06170970?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06170970 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

Multiple Sclerosis Fatigue

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.